Study Evaluating GSI-953 in Healthy Young and Alzheimer's Patients

Summary

To assess the pharmacodynamics (PD) of biomarkers amyloid beta peptide 40 and 42 (Ab40 and Ab42) in CSF, following single oral doses of GSI-953, an investigational drug, in healthy young subjects and patients with Alzheimer Disease (AD).

Timeline

Start

2007-05

Primary completion

2007-10

Completion

2007-10

Drugs

Indications